加载中
Seer, Inc. is a life sciences firm specializing in developing and commercializing advanced technologies designed to unravel the complexities of the proteome. At the core of its offerings is the Proteograph Product Suite, an integrated platform comprising specialized consumables, automated instrumentation, and sophisticated software. This comprehensive solution empowers researchers to conduct advanced proteomic studies across various applications, including therapeutic and diagnostic investigations, as well as clinical trials. The company markets its products exclusively for research applications, serving academic institutions, diverse life sciences and research laboratories, and biopharmaceutical and biotechnology enterprises. Notably, these offerings are intended for non-diagnostic and non-clinical purposes. Seer has established collaborative agreements with entities such as Discovery Life Sciences, LLC, and the Salk Institute for Biological Studies. Originally incorporated in 2017 as Seer Biosciences, Inc., the company adopted its current name, Seer, Inc., in July 2018. Its headquarters are situated in Redwood City, California.
前收盘价
US$2.15
−US$0.04 · -1.83%
盘后
US$2.15
US$0.00 · 0.00%
10月12日 19:30 ET
盘中时间采用ET。市场数据可能有所延迟。
Seer, Inc. is a life sciences firm specializing in developing and commercializing advanced technologies designed to unravel the complexities of the proteome. At the core of its offerings is the Proteograph Product Suite, an integrated platform comprising specialized consumables, automated instrumentation, and sophisticated software. This comprehensive solution empowers researchers to conduct advanced proteomic studies across various applications, including therapeutic and diagnostic investigations, as well as clinical trials. The company markets its products exclusively for research applications, serving academic institutions, diverse life sciences and research laboratories, and biopharmaceutical and biotechnology enterprises. Notably, these offerings are intended for non-diagnostic and non-clinical purposes. Seer has established collaborative agreements with entities such as Discovery Life Sciences, LLC, and the Salk Institute for Biological Studies. Originally incorporated in 2017 as Seer Biosciences, Inc., the company adopted its current name, Seer, Inc., in July 2018. Its headquarters are situated in Redwood City, California.
日内区间
当前US$2.15
52周区间
当前US$2.15
盘中时间采用ET。市场数据可能有所延迟。
Seer, Inc. is a life sciences firm specializing in developing and commercializing advanced technologies designed to unravel the complexities of the proteome. At the core of its offerings is the Proteograph Product Suite, an integrated platform comprising specialized consumables, automated instrumentation, and sophisticated software. This comprehensive solution empowers researchers to conduct advanced proteomic studies across various applications, including therapeutic and diagnostic investigations, as well as clinical trials. The company markets its products exclusively for research applications, serving academic institutions, diverse life sciences and research laboratories, and biopharmaceutical and biotechnology enterprises. Notably, these offerings are intended for non-diagnostic and non-clinical purposes. Seer has established collaborative agreements with entities such as Discovery Life Sciences, LLC, and the Salk Institute for Biological Studies. Originally incorporated in 2017 as Seer Biosciences, Inc., the company adopted its current name, Seer, Inc., in July 2018. Its headquarters are situated in Redwood City, California.
日内区间
当前US$2.15
52周区间
当前US$2.15
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 1611.9万 USD | 1394.7万 USD | 1518.2万 USD | 1468.5万 USD | 639.4万 USD |
| 销货成本 | 811.3万 USD | 711.5万 USD | 1373.3万 USD | 1430.1万 USD | 676.8万 USD |
| 毛利 | 800.6万 USD | 683.2万 USD | 144.9万 USD | 38.4万 USD | −37.4万 USD |
| 研究与开发 | 4387.4万 USD | 5058.5万 USD | 4744.1万 USD | 4579.7万 USD | 2912.1万 USD |
| 销售、一般及管理费用 | 4258.3万 USD | 5657.1万 USD | 5895万 USD | 5263万 USD | 4220.1万 USD |
| 营业费用 | 8599.8万 USD | 1.07亿 USD | 1.06亿 USD | 9842.7万 USD | 7132.2万 USD |
| 利息收入 | 1152.2万 USD | 1666.6万 USD | 1776.4万 USD | 460.2万 USD | 32.6万 USD |
| 利息支出 | — | — | — | — | 2.2万 USD |
| 折旧和摊销 | 610.4万 USD | 617.6万 USD | 557.8万 USD | 394.2万 USD | 255.8万 USD |
| 营业利润 | −7799.2万 USD | −1亿 USD | −1.05亿 USD | −9804.3万 USD | −7169.6万 USD |
| 净利润 | −7360万 USD | −8659.9万 USD | −8627.7万 USD | −9296.6万 USD | −7116.9万 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$4.00
上涨空间 86.05%评级样本有限，仅4项
报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI239.46万0.00%2.3万亿 USD0.03%US$381.57-0.10%
Vanguard Extended Market ETFVXF78万0.00%954亿 USD0.05%US$233.52-0.63%
iShares Micro-Cap ETFIWC29.09万0.02%13.17亿 USD0.60%US$181.66-0.73%
EA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSM14万0.12%1.16亿 USD0.73%US$15.8484-0.58%
Avantis U.S. Small Cap Equity ETFAVSC13.48万—30.82亿 USD0.25%US$69.97-0.01%
U.S. Micro Cap Portfolio ETFDFMC8.28万0.00%75.58亿 USD0.43%US$57.70-0.20%
Invesco RAFI US 1500 Small-Mid ETFPRFZ5.06万0.00%26.7亿 USD0.36%US$52.92-0.45%
Dimensional - US Small Cap ETFDFAS3.41万0.00%338.69亿 USD0.31%US$78.17-0.23%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Micro-Cap ETFIWCEA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSMAvantis U.S. Small Cap Equity ETFAVSCU.S. Micro Cap Portfolio ETFDFMCInvesco RAFI US 1500 Small-Mid ETFPRFZDimensional - US Small Cap ETFDFASAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
